Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2024-06-21 Director's Dealing
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Trading by management and close relations of management
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by a person discharging managerial responsibilities (PDMR) or a closely associated person, specifically citing Article 19 of the EU Market Abuse Regulation (MAR). This is a standard disclosure for insider trading/director dealings. While it mentions an attachment, the text itself contains the full required disclosure details (transaction date, volume, price, and parties involved), making it a primary 'Director's Dealing' filing rather than just an announcement of a report.
2024-06-21 Danish
Earnings Release 2024
Earnings Release Classification · 100% confidence The document text contains an announcement regarding an upgrade to the 2024 outlook (sales growth and EBITDA margin) and provides details about an upcoming Capital Markets Day. It summarizes key financial expectations, synergy targets, and future ambitions. This content is characteristic of an initial release of key financial highlights and forward-looking guidance updates, rather than a comprehensive quarterly report (IR) or a full annual report (10-K). Since it focuses on the immediate release of updated performance metrics and guidance, it aligns best with an Earnings Release (ER). It is not a transcript (CT), a proxy statement (PSI), or a formal audit report (AR). The document is substantial enough (7718 chars) that it is not merely an announcement of a report (RPA/RNS), but the report/release itself. H1 2024
2024-06-17 English
The era of biosolutions. Outlook upgraded for 2024
Earnings Release Classification · 95% confidence The document is a company announcement (Company Announcement no. 21) from Novonesis regarding an upgrade to their 2024 financial outlook and providing details about an upcoming Capital Markets Day. It contains key financial highlights, forward-looking statements, and event logistics. It does not constitute a full financial report, but rather an initial release of updated guidance and event information, which fits the definition of an Earnings Release (ER) or a general regulatory announcement. Given the focus on financial outlook and performance metrics, 'ER' is the most appropriate classification. H1 2024
2024-06-17 English
Director's Dealing 2024
Director's Dealing Classification · 98% confidence The document explicitly discusses 'Trading by management and close relations of management' and cites 'article 19 in Regulation (EU) No 596/2014' (Market Abuse Regulation). This regulation governs insider trading disclosures. The content details transactions by management figures. This directly corresponds to the definition of Director's Dealing (insider trades by directors/executives). The document is short and includes an attachment link, but the core subject matter is the insider transaction report itself, making 'DIRS' the most specific classification over a general 'RPA' or 'RNS'.
2024-05-31 English
Trading by management and close relations of management
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by a person discharging managerial responsibilities (the CFO, Rainer Lehmann). It explicitly cites Regulation (EU) No 596/2014 (Market Abuse Regulation) regarding trading by management and close relations. This aligns perfectly with the definition for 'Director's Dealing' (DIRS).
2024-05-31 English
Director's Dealing 2024
Director's Dealing Classification · 99% confidence The document explicitly discusses 'Trading by management and close relations of management' and cites 'article 19 in Regulation (EU) No 596/2014' (Market Abuse Regulation). This regulation mandates disclosures for transactions by persons discharging managerial responsibilities (PDMRs). The document directs the reader to an 'Attachment' containing the actual transaction details. Since the text itself is a brief announcement pointing to the detailed report of insider trades, it fits the description of Director's Dealing (DIRS) or, given its regulatory nature and brevity, potentially a Regulatory Filing (RNS). However, the content is specifically about insider transactions by management, which strongly aligns with the 'Director's Dealing' definition (DIRS). Given the specific nature of the content (insider trades disclosure) over the general fallback (RNS), DIRS is the most appropriate classification.
2024-05-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.